Lim P W Y, Goh K L
Eisai Asia Regional Services Pte Ltd, Singapore.
J Gastroenterol Hepatol. 2004 Sep;19 Suppl 3:S61-8. doi: 10.1111/j.1440-1746.2004.03592.x.
Proton pump inhibitors (PPI) are the mainstay of gastroesophageal reflux disease (GERD) treatment. They have a good efficacy and short- and long-term safety profile. Rabeprazole is a second generation PPI with rapid onset of action that quickly relieves symptoms of GERD. Rabeprazole consistently and profoundly inhibits gastric acid secretion. Its metabolism is less dependent on CYP4502C19 system and therefore is the least affected among all PPIs by CYP4502C19 genetic polymorphism. Recent studies have also indicated that rabeprazole on-demand is cost effective in preventing non-erosive reflux disease (NERD) symptom relapse.
质子泵抑制剂（PPI）是胃食管反流病（GERD）治疗的主要药物。它们具有良好的疗效以及短期和长期安全性。雷贝拉唑是第二代PPI，起效迅速，能快速缓解GERD症状。雷贝拉唑能持续且显著地抑制胃酸分泌。其代谢较少依赖CYP4502C19系统，因此在所有PPI中受CYP4502C19基因多态性的影响最小。最近的研究还表明，按需服用雷贝拉唑在预防非糜烂性反流病（NERD）症状复发方面具有成本效益。
